Greene promoted to president, COO of Alnylam

CAMBRIDGE, Mass. Alnylam Pharmaceuticals, a biotech company focused on understanding how genes are turned on and off, has announced the promotion of Barry Greene to the new position of president and chief operating officer.

Greene previously held the title of chief operating officer. In his new role, he will assume responsibilities for business, corporate and commercial development activities and will continue to report to the chief executive officer. He has more than 20 years of experience in health care and product development.

Prior to working at Alnylam, Greene was general manager of oncology at Millennium Pharmaceuticals, where he led the company’s global strategy and execution for its oncology business including strategic business direction and execution. He also worked as vice president of marketing and customer service for AstraZeneca.

“We are delighted to promote Barry to the new role of president and chief operating officer. He has excelled in the business leadership of Alnylam and has aptly earned this advancement and new recognition,” said John Maraganore, chief executive officer of Alnylam. “Barry and I have worked together successfully as a team for several years and I look forward to working closely with him over the long term in building Alnylam as a leading biopharmaceutical company founded on RNA interference.”